GlassScriptPhysician profile
Michael N Lokale
NPI 1205147964
$13,597.41
in general payments reported to CMS, 2019-2025
60 companies · $2,423 in 2025
The $2,423 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,039 · 2020: $1,626 · 2021: $1,264 · 2022: $1,723 · 2023: $1,759 · 2024: $2,764 · 2025: $2,423.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,946.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,945.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,929.82 | 2020-2025 | |
| Amgen INC. | $1,360.23 | 2019-2025 | Repatha, Repatha, Otezla |
| Glaxosmithkline, LLC. | $1,236.37 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $1,235.01 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $781.23 | 2019-2025 | Mounjaro, Kisunla, Emgality |
| Pfizer INC. | $664.57 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $601.60 | 2019-2024 | Xifaxan, Trulance |
| Abbott Laboratories | $469.81 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Novo Nordisk INC | $451.76 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $440.58 | 2019-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $389.82 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Novartis Pharmaceuticals Corporation | $353.41 | 2019-2025 | |
| Allergan, INC. | $319.74 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $283.60 | 2019-2024 | Xarelto, Spravato |
| Exact Sciences Corporation | $252.03 | 2023-2025 | Cologuard Collection Kit |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Lokale listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.